These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 35905253)
1. Fever as a first presentation of castration-resistant prostate cancer: A case report. Oh TH; Park SC Medicine (Baltimore); 2022 Jul; 101(30):e29428. PubMed ID: 35905253 [TBL] [Abstract][Full Text] [Related]
2. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061 [TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
5. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report. Kosaka T; Hongo H; Oya M BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946 [TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Satoh T; Uemura H; Tanabe K; Nishiyama T; Terai A; Yokomizo A; Nakatani T; Imanaka K; Ozono S; Akaza H Jpn J Clin Oncol; 2014 Dec; 44(12):1206-15. PubMed ID: 25425730 [TBL] [Abstract][Full Text] [Related]
7. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511 [TBL] [Abstract][Full Text] [Related]
8. Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. Bianchi S; Mosca A; Dalla Volta A; Prati V; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Zamparini M; Sirotova Z; Chiappino I; Dal Canton O; Masini C; Sacco C; Amoroso D; Montagnani F; Comandone A; Bellissimo AR; Ciccone G; Baier S; Gennari A; Tucci M; Berruti A Eur J Cancer; 2021 Sep; 155():127-135. PubMed ID: 34371442 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967 [TBL] [Abstract][Full Text] [Related]
10. A castrate-resistant metastatic prostate cancer patient with severe pancytopenia, successfully treated with docetaxel chemotherapy. Kunthur A J Oncol Pharm Pract; 2020 Jul; 26(5):1254-1258. PubMed ID: 31775579 [TBL] [Abstract][Full Text] [Related]
11. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579 [TBL] [Abstract][Full Text] [Related]
12. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer. Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621 [TBL] [Abstract][Full Text] [Related]
13. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815 [TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187 [TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030 [TBL] [Abstract][Full Text] [Related]
16. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
17. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER]. Nishizawa K; Hattahara K; Onishi H; Yoshida T Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081 [TBL] [Abstract][Full Text] [Related]
18. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer. Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829 [TBL] [Abstract][Full Text] [Related]
19. Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry. Akaza H; Procopio G; Pripatnanont C; Facchini G; Fava S; Wheatley D; Leung KC; Butt M; Silva A; Castillo L; Karavasilis V; Ӧzatılgan A; Hitier S; Ecstein-Fraisse EB; Ӧzgüroḡlu M J Glob Oncol; 2018 Sep; 4():1-12. PubMed ID: 30260754 [TBL] [Abstract][Full Text] [Related]
20. PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel. Shi X; Pei X; Fan J; Liu T; Zhang D; Yang T; Wu K; He D; Li L Andrologia; 2021 May; 53(4):e13916. PubMed ID: 33591598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]